Expanded Access Policy

Context Therapeutics Inc. (Context) is committed to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Context is focused on conducting clinical trials to obtain safety and efficacy information for our investigational product candidates (drugs that have not been approved by regulatory authorities), which is required to gain market approval and broaden accessibility of the product to patients. We understand that, in certain circumstances, it may not be possible for a patient to participate in a clinical trial and may seek special access to an investigational product. Such access is referred to as expanded access, compassionate use, or right-to-try. To ensure adequate supply of investigational products for our ongoing clinical trials, as well as to maintain fair and equitable access, Context does not currently provide its investigational products on an expanded access, compassionate use, or right-to-try basis. Access to our investigational products is currently limited to participation in one of Context’s clinical trials. To learn more about available clinical trials sponsored by Context, please visit www.contexttherapeutics.com/patients or visit https://clinicaltrials.gov/ and search by company, disease, or medicine.

If you have additional questions, please speak with your physician or contact Context at info@contexttherapeutics.com.

Context may revise this policy at any time